<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033488</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069292</org_study_id>
    <secondary_id>UKFOCSS</secondary_id>
    <secondary_id>CRCA-FOCS</secondary_id>
    <secondary_id>EU-20044</secondary_id>
    <nct_id>NCT00033488</nct_id>
  </id_info>
  <brief_title>Screening Women at High Genetic Risk for Ovarian Cancer</brief_title>
  <official_title>The UK Familial Ovarian Cancer Screening Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective&#xD;
      treatment for ovarian cancer.&#xD;
&#xD;
      PURPOSE: Screening trial to determine the best procedure to detect ovarian cancer in women&#xD;
      who have a high genetic risk for developing ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine an optimal screening procedure for ovarian cancer, in terms of the most&#xD;
           appropriate screening test, criteria for interpretation of results, and screening&#xD;
           intervals, in women at high genetic risk for developing ovarian cancer.&#xD;
&#xD;
        -  Determine the physical morbidity and the resource implications associated with ovarian&#xD;
           cancer screening in these women.&#xD;
&#xD;
        -  Assess the feasibility of screening this high-risk population in terms of compliance&#xD;
           rates.&#xD;
&#xD;
      OUTLINE: Patients undergo transvaginal ultrasonography of the ovaries (scheduled for the&#xD;
      early follicular phase, day 3-6 of the menstrual cycle) and CA 125 measurement annually.&#xD;
      Blood samples are collected every 4 months for analysis of CA 125 levels and novel markers.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5,000 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>annual screening</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>comparison of screening methods</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  First-degree relative (mother, sister, or daughter) of an affected member of a&#xD;
             high-risk family defined as one of the following:&#xD;
&#xD;
               -  Family containing 2 or more individuals with ovarian cancer who are connected by&#xD;
                  first-degree relationships&#xD;
&#xD;
               -  Family containing 1 individual with ovarian cancer and 1 individual with breast&#xD;
                  cancer and under 50 years of age at the time of diagnosis who are connected by&#xD;
                  first-degree relationships&#xD;
&#xD;
               -  Family containing 1 individual with ovarian cancer and 2 individuals with breast&#xD;
                  cancer and under 60 years of age at the time of diagnosis who are connected by&#xD;
                  first-degree relationships&#xD;
&#xD;
               -  Family containing an affected individual with a mutation of one of the known&#xD;
                  ovarian cancer predisposing genes&#xD;
&#xD;
               -  Family containing 3 individuals with colorectal cancer with at least 1 individual&#xD;
                  under 50 years of age at time of diagnosis and 1 individual with ovarian cancer&#xD;
                  who are connected by first-degree relationships&#xD;
&#xD;
               -  Families where affected relatives are related by second-degree relationships&#xD;
                  through an unaffected intervening male relative who has an affected daughter are&#xD;
                  allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  35 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior bilateral oophorectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent participation in other ovarian cancer screening trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Mackay, MD, MA, FRCP, FRCPE</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Child Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

